United Therapeutics Corporation (UTHR) Analysts See $3.51 EPS

April 24, 2018 - By Vivian Currie

United Therapeutics Corporation (NASDAQ:UTHR) LogoInvestors sentiment increased to 1.14 in Q4 2017. Its up 0.15, from 0.99 in 2017Q3. It improved, as 26 investors sold United Therapeutics Corporation shares while 112 reduced holdings. 53 funds opened positions while 105 raised stakes. 40.90 million shares or 1.42% less from 41.49 million shares in 2017Q3 were reported.
Us Bank & Trust De invested in 5,325 shares or 0% of the stock. Etrade Cap Mgmt Llc, New York-based fund reported 2,937 shares. Fisher Asset Ltd holds 0% or 2,649 shares. Hl Fincl Services Limited Liability reported 0% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Jane Street Limited Liability Corp has invested 0% in United Therapeutics Corporation (NASDAQ:UTHR). First Trust Lp has invested 0.18% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). X Management Ltd Liability Corp owns 257 shares. Livforsakringsbolaget Skandia Omsesidigt invested in 5,639 shares or 0.08% of the stock. Old Mutual Global (Uk) Limited reported 937,889 shares. State Of Alaska Department Of Revenue accumulated 2,600 shares. Geode Capital Management Limited Liability Com owns 685,359 shares for 0.03% of their portfolio. Ameritas Investment Prtnrs Inc has 13,017 shares for 0.09% of their portfolio. Oppenheimer And Com Incorporated reported 1,616 shares stake. Tudor Investment Et Al reported 4,085 shares. Connor Clark Lunn Inv Mngmt owns 80,613 shares or 0.07% of their US portfolio.

Since October 26, 2017, it had 0 insider buys, and 10 sales for $26.79 million activity.

Analysts expect United Therapeutics Corporation (NASDAQ:UTHR) to report $3.51 EPS on April, 25.They anticipate $0.38 EPS change or 9.77 % from last quarter’s $3.89 EPS. UTHR’s profit would be $151.79 million giving it 7.76 P/E if the $3.51 EPS is correct. After having $2.06 EPS previously, United Therapeutics Corporation’s analysts see 70.39 % EPS growth. The stock decreased 2.30% or $2.56 during the last trading session, reaching $108.94. About 127,930 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since April 24, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage

Among 5 analysts covering United Therapeutics (NASDAQ:UTHR), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. United Therapeutics had 10 analyst reports since October 26, 2017 according to SRatingsIntel. The firm has “Buy” rating by Wedbush given on Monday, November 13. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Underperform” rating given on Thursday, February 22 by Credit Suisse. The rating was upgraded by Credit Suisse to “Neutral” on Tuesday, April 3. The firm has “Buy” rating given on Wednesday, December 27 by Wedbush. The stock has “Buy” rating by Wedbush on Thursday, January 4. The firm earned “Hold” rating on Thursday, October 26 by Cowen & Co. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Underweight” rating given on Thursday, February 22 by Barclays Capital. H.C. Wainwright maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Thursday, October 26. H.C. Wainwright has “Hold” rating and $95.0 target. Wedbush maintained the stock with “Buy” rating in Tuesday, February 27 report.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $4.71 billion. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 11.7 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.